Rep. Kevin Hern Sells Off Shares of Medtronic PLC (NYSE:MDT)

Representative Kevin Hern (Republican-Oklahoma) recently sold shares of Medtronic PLC (NYSE:MDT). In a filing disclosed on September 01st, the Representative disclosed that they had sold between $15,001 and $50,000 in Medtronic stock on August 24th. The trade occurred in the Representative’s “HERN FAMILY FOUNDATION” account.

Representative Kevin Hern also recently made the following trade(s):

• Sold $1,001 – $15,000 in shares of Marsh & McLennan Companies (NYSE:MRSH) on 8/24/2026.
• Sold $50,001 – $100,000 in shares of Home Depot (NYSE:HD) on 8/24/2026.
• Sold $50,001 – $100,000 in shares of Procter & Gamble (NYSE:PG) on 8/24/2026.
• Sold $1,001 – $15,000 in shares of Lowe’s Companies (NYSE:LOW) on 8/24/2026.
• Sold $15,001 – $50,000 in shares of Microsoft (NASDAQ:MSFT) on 8/21/2026.
• Sold $1,001 – $15,000 in shares of Veralto (NYSE:VLTO) on 8/21/2026.
• Sold $15,001 – $50,000 in shares of Honeywell Aerospace (NASDAQ:HONA) on 8/19/2026.
• Sold $1,001 – $15,000 in shares of Colgate-Palmolive (NYSE:CL) on 8/19/2026.
• Sold $1,001 – $15,000 in shares of Biogen (NASDAQ:BIIB) on 8/18/2026.
• Sold $1,001 – $15,000 in shares of Anheuser-Busch InBev SA/NV (NYSE:BUD) on 8/18/2026.

Medtronic Stock Up 0.7%

NYSE:MDT opened at $92.87 on Friday. The business’s fifty day moving average price is $86.52 and its 200 day moving average price is $85.31. The firm has a market capitalization of $118.87 billion, a price-to-earnings ratio of 22.87, a PEG ratio of 2.16 and a beta of 0.56. The company has a current ratio of 2.13, a quick ratio of 1.62 and a debt-to-equity ratio of 0.52. Medtronic PLC has a 1-year low of $73.31 and a 1-year high of $106.33.

Medtronic (NYSE:MDT) last announced its quarterly earnings data on Tuesday, September 1st. The medical technology company reported $1.45 EPS for the quarter, topping analysts’ consensus estimates of $1.39 by $0.06. Medtronic had a return on equity of 14.89% and a net margin of 13.93%.The firm had revenue of $9.76 billion during the quarter, compared to analyst estimates of $9.55 billion. During the same period last year, the company posted $1.26 EPS. The business’s quarterly revenue was up 13.7% compared to the same quarter last year. Medtronic has set its Q2 2027 guidance at 1.320-1.340 EPS and its FY 2027 guidance at 5.940-6.000 EPS. On average, sell-side analysts forecast that Medtronic PLC will post 5.95 earnings per share for the current fiscal year.

Medtronic Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Friday, October 16th. Investors of record on Friday, September 25th will be given a dividend of $0.72 per share. This represents a $2.88 annualized dividend and a yield of 3.1%. The ex-dividend date of this dividend is Friday, September 25th. Medtronic’s payout ratio is presently 70.94%.

Institutional Trading of Medtronic

Several large investors have recently modified their holdings of the company. Ipsen Advisor Group LLC lifted its position in Medtronic by 1.7% during the 4th quarter. Ipsen Advisor Group LLC now owns 5,952 shares of the medical technology company’s stock worth $572,000 after acquiring an additional 101 shares during the last quarter. Quadrant Capital Group LLC boosted its holdings in Medtronic by 0.3% during the fourth quarter. Quadrant Capital Group LLC now owns 32,477 shares of the medical technology company’s stock valued at $3,120,000 after acquiring an additional 101 shares during the period. Rossby Financial LCC grew its position in shares of Medtronic by 5.1% in the fourth quarter. Rossby Financial LCC now owns 2,193 shares of the medical technology company’s stock valued at $211,000 after purchasing an additional 107 shares during the last quarter. Wealthspire Retirement LLC grew its position in shares of Medtronic by 5.0% in the fourth quarter. Wealthspire Retirement LLC now owns 2,410 shares of the medical technology company’s stock valued at $232,000 after purchasing an additional 114 shares during the last quarter. Finally, Mitchell Mcleod Pugh & Williams Inc. increased its stake in shares of Medtronic by 2.0% in the fourth quarter. Mitchell Mcleod Pugh & Williams Inc. now owns 6,043 shares of the medical technology company’s stock worth $622,000 after purchasing an additional 117 shares during the period. 82.06% of the stock is owned by institutional investors.

Analyst Ratings Changes

A number of analysts have recently issued reports on MDT shares. TD Cowen increased their price target on shares of Medtronic from $100.00 to $110.00 and gave the stock a “buy” rating in a research report on Friday, August 28th. Sanford C. Bernstein lowered their price target on Medtronic from $112.00 to $97.00 and set an “outperform” rating for the company in a research note on Thursday, June 4th. Wall Street Zen upgraded shares of Medtronic from a “hold” rating to a “buy” rating in a research note on Saturday, July 18th. Leerink Partners dropped their price target on shares of Medtronic from $117.00 to $104.00 and set an “outperform” rating on the stock in a research note on Thursday, June 4th. Finally, Wells Fargo & Company lifted their price objective on shares of Medtronic from $102.00 to $104.00 and gave the company an “overweight” rating in a research note on Wednesday. Nineteen equities research analysts have rated the stock with a Buy rating and nine have assigned a Hold rating to the company’s stock. Based on data from MarketBeat, Medtronic currently has a consensus rating of “Moderate Buy” and an average price target of $103.92.

Key Medtronic News

Here are the key news stories impacting Medtronic this week:

• Positive Sentiment: Medtronic’s fiscal first-quarter results exceeded expectations, with adjusted EPS of $1.45 versus the $1.39 consensus and revenue of $9.76 billion versus $9.55 billion expected. Revenue increased 13.7% year over year, while management raised its fiscal 2027 outlook to approximately $5.94-$6.00 in EPS. Medtronic Begins Fiscal 2027 With a Beat-and-Raise
• Positive Sentiment: Analysts responded favorably to the earnings beat and raised guidance. RBC reaffirmed its Outperform rating with a $118 price target, while TD Cowen maintained a Buy rating; other firms also increased their targets. Medtronic Analysts Raise Their Forecasts
• Positive Sentiment: Management highlighted broad-based growth across major franchises and newer platforms, including robotics and ablation. Investors view this as evidence that Medtronic’s multiyear growth recovery may be gaining momentum. MDT Earnings Call Focuses on Broad Growth
• Positive Sentiment: A PERSIST addendum study is generating additional real-world evidence for Medtronic’s Inceptiv spinal cord stimulation system, potentially strengthening physician adoption and investor confidence. Medtronic’s PERSIST Study
• Positive Sentiment: Medtronic entered a strategic partnership with Cornerstone Robotics intended to expand global access to robot-assisted surgery, supporting its long-term robotics strategy. Cornerstone Robotics Partnership
• Negative Sentiment: Market strategists warned that Medtronic has become a crowded healthcare-sector trade. The recommendation included using options to bet on a decline, reflecting concern that excessive bullish positioning could limit further gains or trigger a pullback. Crowded Healthcare Stocks

Insider Buying and Selling at Medtronic

In related news, EVP Harry Kiil sold 4,189 shares of the business’s stock in a transaction dated Monday, June 8th. The stock was sold at an average price of $80.44, for a total transaction of $336,963.16. Following the completion of the transaction, the executive vice president owned 37,227 shares of the company’s stock, valued at approximately $2,994,539.88. The trade was a 10.11% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Corporate insiders own 0.27% of the company’s stock.

About Representative Hern

Kevin Hern (Republican Party) is a member of the U.S. House, representing Oklahoma’s 1st Congressional District. He assumed office on November 13, 2018. His current term ends on January 3, 2027.

Hern (Republican Party) is running for re-election to the U.S. House to represent Oklahoma’s 1st Congressional District. He declared candidacy for the 2026 election.

Kevin Hern went into business as a McDonald’s franchisee in 1999. He acquired 10 McDonald’s franchises by 2012. He served on the McDonald’s National Leadership Team for 13 years, including the tax policy team, the insurance corporation, and as chairman of the economics team. From 2011 to 2015, he was chairman of the finance committee of the Oklahoma Turnpike Authority.

Medtronic Company Profile

Medtronic plc is a global medical technology company that develops and manufactures a broad range of therapeutic devices and health care solutions. Headquartered legally in Ireland with principal operational offices in the United States, the company markets products to hospitals, physicians and health systems worldwide and has grown from its founding in 1949 into one of the largest medical-device manufacturers serving global health-care markets.

Medtronic’s offerings span several clinical areas, including cardiac rhythm and heart failure (pacemakers, implantable cardioverter?defibrillators and related cardiac therapies), minimally invasive and surgical technologies (laparoscopic and advanced energy devices, visualization systems and surgical innovations), restorative therapies (spine and orthopedics, neuromodulation and neurovascular treatments) and diabetes management (insulin-delivery systems and glucose monitoring solutions).